• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novaliq GmbH

Novaliq touts topline data for dry eye disease drug

October 18, 2018 By Sarah Faulkner

Novaliq logo updated

Novaliq today touted topline data from the first pivotal trial of its CyclASol 0.1% drug designed to treat dry eye disease. The company is hoping to position its 0.1% cyclosporine A product as advantageous compared to other ophthalmic treatments, noting that its EyeSol technology helps boost the drug’s efficacy and provide an earlier onset of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Research & Development Tagged With: Novaliq GmbH

Novaliq enrolls first patient in Ph2 dry eye disease trial

January 8, 2018 By Sarah Faulkner

Novaliq

Novaliq said today that it has begun randomizing patients in a Phase II trial of its product candidate for dry eye disease. Patients with evaporative dry eye disease caused by Meibomian gland dysfunction have impaired tear film lipid layers, according to the specialty pharma company, and treatment options for these patients are limited. Novaliq’s NOV03 […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Novaliq GmbH

Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease

December 8, 2017 By Sarah Faulkner

Novaliq

Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe. The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Novaliq GmbH

Novaliq’s NovaTears dry eye disease therapy launches in New Zealand

October 30, 2017 By Sarah Faulkner

Novaliq

Novaliq today launched its dry eye disease therapy, NovaTears, in New Zealand and said that it won registrational approval in Australia. The Germany-based company inked an exclusive licensing partnership earlier this year with AFT Pharmaceuticals (ASX:AFP) to commercialize Novaliq’s water-free topical eye drops in Australia. “NovaTears is a first-in-class treatment for this common and highly underserved […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: AFT Pharmaceuticals, Novaliq GmbH

Milestone Scientific appoints new CEO following FDA nod | Personnel Moves – July 13, 2017

July 13, 2017 By Sarah Faulkner

Milestone Scientific

Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations. The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AstraZeneca plc, Avalon, Biogen Idec, cingulatetherapeutics, foamixpharmaceuticals, Gamida Cell, Ipsen, mannkind, milestonescientific, Novaliq GmbH, portal instruments

Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy

March 21, 2017 By Sarah Faulkner

Ocular therapeutics company Novaliq said today that it inked a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of its dry eye therapy, NovaTears, in Australia and New Zealand. NovaTears is the Germany-based company’s 1st commercially available product indicated for the treatment of evaporative dry eye diseases. According to the agreement, AFT has an exclusive […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: AFT Pharmaceuticals, Novaliq GmbH

Ocular therapeutics company Novaliq names new CEO

October 7, 2016 By Sarah Faulkner

Novaliq GmbH said yesterday that it named Christian Roesky as its new CEO, replacing co-founder Bernhard Günther, who will take on a new role as chief innovation officer. The Heidelberg, Germany-based company focuses on renovating poorly soluble drugs into effective ocular therapeutics. Its CE-marked product, NovaTears, was developed from its proprietary EyeSol technology. With its […]

Filed Under: Optical/Ophthalmic, Personnel, Pharmaceuticals Tagged With: Novaliq GmbH

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS